



IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards

London, 22 August 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has been shortlisted as a finalist in the 2018 OBN Awards in the “Best Start-up Biotech Company” category.

The “Best Start-up Biotech Company” award recognises a UK registered start-up biotech company that was incorporated on or after 1 June 2016, is making an impact on the industry via significant news flow, has successfully raised seed or Series A fundraising, is conducting early clinical trial activity and can demonstrate clear evidence of early stage implementation of a robust business plan.

2018 marks the 10th Anniversary of the OBN Awards, which recognise the leading lights of the life sciences industry in the UK. The winners will be announced at the OBN Awards evening on Thursday 11 October at the Examination Schools in Oxford.

Dr Tim Wilson, Chief Executive Officer of IGEM, commented: “We are delighted that IGEM Therapeutics has been shortlisted as a finalist in the “Best Start-up Biotech Company” category at the OBN Awards. To be considered for these prestigious awards is recognition of our efforts to develop novel immunoglobulin E (IgE) antibodies for the treatment of cancer.”

ENDS

About IGEM Therapeutics

IGEM is a UK immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. Unlike immunoglobulin G (IgG), IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours.

Pre-clinical proof of concept has been obtained with two different IgE antibodies both showing significantly greater efficacy versus IgG comparators. IGEM is a spin out of King’s College London and has an ongoing collaboration with Dr. Sophia Karagiannis, a global leader in the understanding of IgE antibodies.

For further information visit www.igemtherapeutics.com

For more information please contact:

Tim Wilson
Chief Executive Officer
IGEM Therapeutics
tim@igemtherapeutics.com
+44 (0)20 3078 9675

Communications advisor to IGEM Therapeutics:
Simon Conway
Senior Managing Director
FTI Consulting
simon.conway@fticonsulting.com
+44 (0)20 3727 1000